<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>6294</number>
    <updateDate>2023-01-11T13:42:15Z</updateDate>
    <updateDateIncludingText>2023-01-11T13:42:15Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <type>HR</type>
    <introducedDate>2018-06-28</introducedDate>
    <congress>115</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 164, Number 109 (Thursday, June 28, 2018)]From the Congressional Record Online through the Government Publishing Office [<a href='http://www.gpo.gov'>www.gpo.gov</a>]By Mr. SHIMKUS:H.R. 6294.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8, Clause 3: To regulate Commerce withforeign Nations, and among the several States, and with theIndian Tribes.[Page H5977]</pre>]]></constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2018-06-28T13:04:25Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <actions>
      <item>
        <actionDate>2018-06-28</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2018-06-28</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2018-06-28</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>S000364</bioguideId>
        <fullName>Rep. Shimkus, John [R-IL-15]</fullName>
        <firstName>JOHN</firstName>
        <lastName>SHIMKUS</lastName>
        <party>R</party>
        <state>IL</state>
        <middleName>M.</middleName>
        <district>15</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <cosponsors>
      <item>
        <bioguideId>C001097</bioguideId>
        <fullName>Rep. Cárdenas, Tony [D-CA-29]</fullName>
        <firstName>Tony</firstName>
        <lastName>Cárdenas</lastName>
        <party>D</party>
        <state>CA</state>
        <district>29</district>
        <sponsorshipDate>2018-06-28</sponsorshipDate>
        <isOriginalCosponsor>True</isOriginalCosponsor>
      </item>
      <item>
        <bioguideId>E000215</bioguideId>
        <fullName>Rep. Eshoo, Anna G. [D-CA-18]</fullName>
        <firstName>ANNA</firstName>
        <lastName>ESHOO</lastName>
        <party>D</party>
        <state>CA</state>
        <middleName>G.</middleName>
        <district>18</district>
        <sponsorshipDate>2018-07-24</sponsorshipDate>
        <isOriginalCosponsor>False</isOriginalCosponsor>
      </item>
    </cosponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Advisory bodies</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Drug therapy</name>
        </item>
        <item>
          <name>Government studies and investigations</name>
        </item>
        <item>
          <name>Health promotion and preventive care</name>
        </item>
        <item>
          <name>Infectious and parasitic diseases</name>
        </item>
        <item>
          <name>Intellectual property</name>
        </item>
        <item>
          <name>Licensing and registrations</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2018-06-28</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2019-08-20T18:49:34Z</updateDate>
        <text><![CDATA[ <p><b>Re-Valuing Anti-Microbial Products Act of 2018 or the REVAMP Act</b></p> <p>This bill amends the Federal Food, Drug, and Cosmetic Act to provide for an award of 12 additional months of market exclusivity to a drug manufacturer for a drug designated as a &quot;priority antimicrobial product.&quot; (A priority antimicrobial product is intended to treat or prevent a disease attributable to a multi-drug resistant bacterial or fungal pathogen for which there is a critical unmet medical need.)</p>]]></text>
      </summary>
    </summaries>
    <title>REVAMP Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>REVAMP Act</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To amend the Federal Food, Drug, and Cosmetic Act to encourage the development of priority antimicrobial products through the award of a transferable exclusivity extension period, and for other purposes.</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>REVAMP Act</title>
      </item>
      <item>
        <titleType>Short Titles as Introduced</titleType>
        <title>Re-Valuing Anti-Microbial Products Act of 2018</title>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2018-06-28T04:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-115hr6294ih/xml/BILLS-115hr6294ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2018-06-28</actionDate>
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
